Andrew W Stamford
Overview
Explore the profile of Andrew W Stamford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nie D, Tabor J, Li J, Kutera M, St-Germain J, Hanley R, et al.
Nat Chem Biol
. 2024 Jul;
20(12):1597-1607.
PMID: 38965384
Targeted protein degradation (TPD) is an emerging therapeutic strategy that would benefit from new chemical entities with which to recruit a wider variety of ubiquitin E3 ligases to target proteins...
2.
Michino M, Khan T, Miller M, Fukase Y, Vendome J, Adura C, et al.
ACS Med Chem Lett
. 2024 Apr;
15(4):524-532.
PMID: 38628784
Eleven-nineteen leukemia (ENL) is an epigenetic reader protein that drives oncogenic transcriptional programs in acute myeloid leukemia (AML). AML is one of the deadliest hematopoietic malignancies, with an overall 5-year...
3.
Nie D, Tabor J, Li J, Kutera M, St-Germain J, Hanley R, et al.
bioRxiv
. 2023 Nov;
PMID: 37961297
Targeted protein degradation (TPD) is an emerging therapeutic strategy that would benefit from new chemical entities with which to recruit a wider variety of ubiquitin E3 ligases to target proteins...
4.
Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
Liu Y, Li Q, Alikarami F, Barrett D, Mahdavi L, Li H, et al.
Cancer Discov
. 2022 Sep;
12(11):2684-2709.
PMID: 36053276
Significance: AML is a poor-prognosis disease for which new therapeutic approaches are desperately needed. We developed an orally bioavailable inhibitor of ENL, demonstrated its potent efficacy in MLL-rearranged and NPM1-mutated...
5.
Kwon J, Hajian B, Bian Y, Young L, Amor A, Fuller J, et al.
Nature
. 2022 Jul;
609(7926):408-415.
PMID: 35831509
Receptor tyrosine kinase (RTK)-RAS signalling through the downstream mitogen-activated protein kinase (MAPK) cascade regulates cell proliferation and survival. The SHOC2-MRAS-PP1C holophosphatase complex functions as a key regulator of RTK-RAS signalling...
6.
Liang R, Tomita D, Sasaki Y, Ginn J, Michino M, Huggins D, et al.
ACS Med Chem Lett
. 2022 Mar;
13(3):377-387.
PMID: 35300079
Aberrant gene-silencing through dysregulation of polycomb protein activity has emerged as an important oncogenic mechanism in cancer, implicating polycomb proteins as important therapeutic targets. Recently, an inhibitor targeting EZH2, the...
7.
Singh K, Lin J, Lecomte N, Mohan P, Gokce A, Sanghvi V, et al.
Cancer Res
. 2021 Feb;
81(8):2002-2014.
PMID: 33632898
Pancreatic adenocarcinoma (PDAC) epitomizes a deadly cancer driven by abnormal KRAS signaling. Here, we show that the eIF4A RNA helicase is required for translation of key KRAS signaling molecules and...
8.
Mullarky E, Xu J, Robin A, Huggins D, Jennings A, Noguchi N, et al.
Bioorg Med Chem Lett
. 2019 Jul;
29(17):2503-2510.
PMID: 31327531
Cancer cells reprogram their metabolism to support growth and to mitigate cellular stressors. The serine synthesis pathway has been identified as a metabolic pathway frequently altered in cancers and there...
9.
Mandal M, Mitra K, Grotz D, Lin X, Palamanda J, Kumari P, et al.
J Med Chem
. 2018 Nov;
61(23):10700-10708.
PMID: 30388368
Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively,...
10.
Neelamkavil S, Stamford A, Kowalski T, Biswas D, Boyle C, Chackalamannil S, et al.
ACS Med Chem Lett
. 2018 May;
9(5):457-461.
PMID: 29795759
The ever-growing prevalence of type 2 diabetes in the world has necessitated an urgent need for multiple orally effective agents that can regulate glucose homeostasis with a concurrent reduction in...